A. Rickinson and E. Kieff, Epstein-Barr virus Fields Virology, Lippincot-Raven, pp.2397-2446, 1996.

H. Delecluse, R. Feederle, . Sullivan, and P. Taniere, Epstein Barr virus-associated tumours: an update for the attention of the working pathologist, Journal of Clinical Pathology, vol.60, issue.12, pp.1358-1364, 2007.
DOI : 10.1136/jcp.2006.044586

H. Abali, Y. Urün, B. Oksüzoglu, B. Budakoglu, N. Yildirim et al., Comparison of ICE (Ifosfamide-Carboplatin-Etoposide) Versus DHAP (Cytosine Arabinoside-Cisplatin-Dexamethasone) as Salvage Chemotherapy in Patients with Relapsed or Refractory Lymphoma, Cancer Investigation, vol.92, issue.4, pp.401-406, 2008.
DOI : 10.1056/NEJM199811193392104

N. Milpied, B. Vasseur, N. Parquet, J. Garnier, C. Antoine et al., Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients, Annals of Oncology, vol.11, issue.suppl 1, pp.113-116, 2000.
DOI : 10.1093/annonc/11.suppl_1.S113

K. Geletneky, Y. Herrero, M. Calle, . Rommelaere, and J. Schlehofer, Oncolytic Potential of Rodent Parvoviruses for Cancer Therapy in Humans: A Brief Review, Journal of Veterinary Medicine Series B, vol.91, issue.7-8, pp.327-330, 2005.
DOI : 10.1093/jnci/93.12.903

T. Bashir, R. Horlein, W. Rommelaere, and K. , Cyclin A activates the DNA polymerase delta -dependent elongation machinery in vitro: A parvovirus DNA replication model, Proceedings of the National Academy of Sciences, vol.97, issue.10, pp.5522-5527, 2000.
DOI : 10.1073/pnas.090485297

M. Perros, L. Deleu, J. Vanacker, Z. Kherrouche, N. Spruyt et al., Upstream CREs participate in the basal activity of minute virus of mice promoter P4 and in its stimulation in ras-transformed cells, J Virol, vol.69, pp.5506-5515, 1995.

S. Mousset, Y. Ouadrhiri, . Caillet-fauquet, and J. Rommelaere, The cytotoxicity of the autonomous parvovirus minute virus of mice nonstructural proteins in FR3T3 rat cells depends on oncogene expression, J Virol, vol.68, pp.6446-6453, 1994.

P. Caillet-fauquet, M. Perros, A. Brandenburger, . Spegelaere, and J. Rommelaere, Programmed killing of human cells by means of an inducible clone of parvoviral genes encoding non-structural proteins, EMBO J, vol.9, pp.2989-2995, 1990.

B. Rayet, J. Lopez-guerrero, . Rommelaere, and C. Dinsart, Induction of programmed cell death by parvovirus H-1 in U937 cells: connection with the tumor necrosis factor alpha signalling pathway, J Virol, vol.72, pp.8893-8903, 1998.

Z. Ran, B. Rayet, . Rommelaere, and S. Faisst, Parvovirus H-1-induced cell death: influence of intracellular NAD consumption on the regulation of necrosis and apoptosis, Virus Research, vol.65, issue.2, pp.161-174, 1999.
DOI : 10.1016/S0168-1702(99)00115-X

M. Moehler, B. Blechacz, N. Weiskopf, M. Zeidler, W. Stremmel et al., Effective infection, apoptotic cell killing and gene transfer of human hepatoma cells but not primary hepatocytes by parvovirus H1 and derived vectors, Cancer Gene Therapy, vol.8, issue.3, pp.158-167, 2001.
DOI : 10.1038/sj.cgt.7700288

D. Piazza, M. Mader, C. Geletneky, K. Herrero, Y. Calle et al., Cytosolic Activation of Cathepsins Mediates Parvovirus H-1-Induced Killing of Cisplatin and TRAIL-Resistant Glioma Cells, Journal of Virology, vol.81, issue.8, pp.4186-4198, 2007.
DOI : 10.1128/JVI.02601-06

S. Faisst, D. Guittard, A. Benner, J. Cesbron, J. Schlehofer et al., Dose-dependent regression of HeLa cell-derived tumours in SCID mice after parvovirus H-1 infection, International Journal of Cancer, vol.66, issue.4, pp.584-589, 1998.
DOI : 10.1002/(SICI)1097-0215(19980209)75:4<584::AID-IJC15>3.0.CO;2-9

T. Dupressoir, J. Vanacker, J. Cornelis, . Duponchel, and J. Rommelaere, Inhibition by parvovirus H-1 of the formation of tumors in nude mice and colonies in vitro by transformed human mammary epithelial cells, Cancer Res, vol.49, pp.3203-3208, 1989.

A. Angelova, M. Aprahamian, . Grekova, . Sp, A. Hajri et al., Improvement of Gemcitabine-Based Therapy of Pancreatic Carcinoma by Means of Oncolytic Parvovirus H-1PV, Clinical Cancer Research, vol.15, issue.2, pp.511-519, 2009.
DOI : 10.1158/1078-0432.CCR-08-1088

URL : https://hal.archives-ouvertes.fr/pasteur-00748222

J. Rommelaere and J. Cornelis, Antineoplasic activity of parvoviruses, Journal of Virological Methods, vol.33, issue.3, pp.233-251, 1991.
DOI : 10.1016/0166-0934(91)90024-T

S. Faisst, . Schlehofer, and H. Zur-hausen, Transformation of human cells by oncogenic viruses supports permissiveness for parvovirus H-1 propagation, J Virol, vol.63, pp.2152-2158, 1989.

S. Faisst, S. Bartnitzke, . Schlehofer, and . Hausen, Persistence of parvovirus H-1 DNA in human B- and T-lymphoma cells, Virus Research, vol.16, issue.2, pp.211-223, 1990.
DOI : 10.1016/0168-1702(90)90024-6

O. Leary, M. Sheaffer, J. Keller, F. Shu, X. Cheson et al., Lymphoma and reticuloendothelial neoplasms Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of, National Cancer Institute, pp.1972-2000, 2006.

H. Heslop, Biology and Treatment of Epstein-Barr Virus-Associated Non-Hodgkin Lymphomas, Hematology, vol.2005, issue.1, pp.260-266, 2005.
DOI : 10.1182/asheducation-2005.1.260

K. Wetzel, S. Struyf, J. Van-damme, T. Kayser, A. Vecchi et al., MCP-3 (CCL7) delivered by parvovirus MVMp reduces tumorigenicity of mouse melanoma cells through activation of T lymphocytes and NK cells, International Journal of Cancer, vol.170, issue.6, pp.1364-1371, 2007.
DOI : 10.1002/ijc.22421

G. Wollmann, P. Tattersall, and A. Van-den-pol, Targeting Human Glioblastoma Cells: Comparison of Nine Viruses with Oncolytic Potential, Journal of Virology, vol.79, issue.10, pp.6005-6022, 2005.
DOI : 10.1128/JVI.79.10.6005-6022.2005

M. Ghetie, . Bright, . Vitetta, and . Es, Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin, Blood, vol.97, issue.5, pp.1392-1398, 2001.
DOI : 10.1182/blood.V97.5.1392

A. Telerman, M. Tuynder, T. Dupressoir, B. Robaye, F. Sigaux et al., A model for tumor suppression using H-1 parvovirus., Proceedings of the National Academy of Sciences, vol.90, issue.18, pp.8702-8706, 1993.
DOI : 10.1073/pnas.90.18.8702

P. Farrell, . Allan, . Gj, F. Shanahan, . Vousden et al., p53 is frequently mutated in Burkitt's lymphoma cell lines, EMBO J, vol.10, pp.2879-2887, 1991.

A. Ichikawa, T. Kinoshita, T. Watanabe, H. Kato, H. Nagai et al., Mutations of the p53 Gene as a Prognostic Factor in Aggressive B-Cell Lymphoma, New England Journal of Medicine, vol.337, issue.8, pp.529-534, 1997.
DOI : 10.1056/NEJM199708213370804

A. Op-de-beeck, F. Anouja, S. Mousset, J. Rommelaere, C. et al., The non-structural proteins of the autonomous parvovirus minute virus of mice interfere with the cell cycle, inducing accumulation in G2, Cell Growth Differ, vol.6, pp.781-787, 1995.

L. Flamand, I. Stefanescu, . Ablashi, and J. Menezes, Activation of the Epstein-Barr virus replicative cycle by human herpesvirus 6, J Virol, vol.67, pp.6768-6777, 1993.

R. Arcenas and R. Widen, Epstein-Barr virus reactivation after superinfection of the BJAB-B1 and P3HR-1 cell lines with cytomegalovirus, BMC Microbiology, vol.2, issue.1, p.20, 2002.
DOI : 10.1186/1471-2180-2-20

A. Henderson, S. Ripley, . Heller, and E. Kieff, Chromosome site for Epstein-Barr virus DNA in a Burkitt tumor cell line and in lymphocytes growth-transformed in vitro., Proceedings of the National Academy of Sciences, vol.80, issue.7, pp.1987-1991, 1983.
DOI : 10.1073/pnas.80.7.1987

W. Hudson, Q. Li, . Le, and J. Kersey, Xenotransplantation of human lymphoid malignancies is optimized in mice with multiple immunologic defects, Leukemia, vol.12, issue.12, pp.2029-2033, 1998.
DOI : 10.1038/sj.leu.2401236

W. Qian, J. Liu, Y. Tong, S. Yan, C. Yang et al., Enhanced antitumor activity by a selective conditionally replicating adenovirus combining with MDA-7/interleukin-24 for B-lymphoblastic leukemia via induction of apoptosis, Leukemia, vol.9, issue.2, pp.361-369, 2008.
DOI : 10.1158/0008-5472.CAN-06-0577

F. Farassati, N. Atanaskova, C. Raffel, . Johnston, and . Lee, Ras signalling as a marker for application of oncolytic herpes mutant against lymphoma, Mol Ther, vol.9, p.26, 2004.

T. Alain, K. Hirasawa, . Pon, . Kj, . Nishikawa et al., Reovirus therapy of lymphoid malignancies, Blood, vol.100, issue.12, pp.4146-4153, 2002.
DOI : 10.1182/blood-2002-02-0503

D. Grote, . Russell, . Sj, . Cornu, . Ti et al., Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice, Blood, vol.97, issue.12, pp.3746-3754, 2001.
DOI : 10.1182/blood.V97.12.3746

J. Pulvertaft, CYTOLOGY OF BURKITT'S TUMOUR (AFRICAN LYMPHOMA), The Lancet, vol.283, issue.7327, pp.238-240, 1964.
DOI : 10.1016/S0140-6736(64)92345-1

M. Rowe, C. Rooney, . Rickinson, . Ab, . Lenoir et al., Distinctions between endemic and sporadic forms of epstein-barr virus-positive burkitt's lymphoma, International Journal of Cancer, vol.417, issue.4, pp.435-441, 1985.
DOI : 10.1002/ijc.2910350404

G. Klein, B. Giovanella, A. Westman, . Stehlin, and D. Mumford, An EBVgenome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection, Intervirology, vol.5, pp.319-334, 1975.

K. Takada, K. Horinouchi, Y. Ono, T. Aya, T. Osato et al., An Epstein-Barr virus-producer line Akata: Establishment of the cell line and analysis of viral DNA, Virus Genes, vol.76, issue.2, pp.147-156, 1991.
DOI : 10.1007/BF00571929

C. Fonatsch, V. Diehl, M. Schaadt, . Burrichter, and H. Kirchner, Cytogenetic investigations in Hodgkin's disease: I. Involvement of specific chromosomes in marker formation, Cancer Genetics and Cytogenetics, vol.20, issue.1-2, pp.39-52, 1986.
DOI : 10.1016/0165-4608(86)90106-8

K. Uehira, R. Amakawa, T. Ito, T. Uehira, Y. Ozaki et al., A Hodgkin???s Disease Cell Line, KM-H2, Shows Biphenotypic Features of Dendritic Cells and B Cells, International Journal of Hematology, vol.94, issue.2, pp.236-244, 2001.
DOI : 10.1007/BF02981944

H. Drexler, G. Gaedicke, . Lok, . Ms, . Diehl et al., Hodgkin's disease derived cell lines HDLM-2 and L-428: Comparison of morphology, immunological and isoenzyme profiles, Leukemia Research, vol.10, issue.5, pp.487-500, 1986.
DOI : 10.1016/0145-2126(86)90084-6

C. Wrzesinski, L. Tesfay, N. Salomé, J. Jauniaux, J. Rommelaere et al., Chimeric and Pseudotyped Parvoviruses Minimize the Contamination of Recombinant Stocks with Replication-Competent Viruses and Identify a DNA Sequence That Restricts Parvovirus H-1 in Mouse Cells, Journal of Virology, vol.77, issue.6, pp.3851-3858, 2003.
DOI : 10.1128/JVI.77.6.3851-3858.2003

N. Giese, Z. Raykov, L. Demartino, A. Vecchi, S. Sozzani et al., Suppression of metastatic hemangiosarcoma by a parvovirus MVMp vector transducing the IP-10 chemokine into immunocompetent mice, Cancer Gene Therapy, vol.9, issue.5, pp.432-442, 2002.
DOI : 10.1038/sj.cgt.7700457

F. Dupont, L. Tenenbaum, . Guo, . Lp, P. Spegelaere et al., Use of an autonomous parvovirus vector for selective transfer of a foreign gene into transformed human cells of different tissue origins and its expression therein, J Virol, vol.68, pp.1397-1406, 1994.